1,228
Participants
Start Date
September 30, 2007
Primary Completion Date
October 31, 2011
Study Completion Date
February 28, 2015
Placebo
Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
Golimumab 50 mg
Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
Golimumab 100 mg
Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
Golimumab 200 mg
Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
Birmingham
Little Rock
Anaheim
Merced
Orange
Roseville
San Diego
Lakewood
Littleton
Bristol
Newark
Boca Raton
Gainesville
Hialeah
Hollywood
Jacksonville
Naples
New Port Richey
North Miami Beach
Port Orange
Tampa
Winter Park
Zephyrhills
Atlanta
Decatur
Savannah
Snellville
Arlington Heights
Chicago
Clive
Fort Dodge
Pratt
Topeka
Lexington
Louisville
Monroe
Hagerstown
Hollywood
Laurel
Worcester
Ann Arbor
Dearborn
Troy
Plymouth
Rochester
Pascagoula
Tupelo
Urbana
Las Vegas
Lebanon
Egg Harbor
Great Neck
Huntington
New York
Rochester
Asheville
Boone
Charlotte
Harrisburg
Kinston
Morganton
New Bern
Raleigh
Wilmington
Winston-Salem
Fargo
Cincinnati
Cleveland
Colombus
Norman
Oklahoma City
Tulsa
Portland
Limerick
Philadelphia
Charleston
Columbia
Germantown
Nashville
Austin
Dallas
Galveston
Houston
Logan
Ogden
Burlington
Chesapeake
Christiansburg
Fairfax
Richmond
Bellevue
Seattle
Spokane
Tacoma
Madison
Milwaukee
Adelaide
Bankstown
Box Hill
Brisbane
Cairns
Fitzroy
Fremantle
Herston
Launceston
Malvern
Parkville
Prahran
Westmead
Innsbruck
Vienna
Bonheiden
Brussels
Ghent
Leuven
Liège
Roeselare
Bulgaria
Pleven
Plovdiv
Rousse
Sofia
Calgary
Vancouver
Victoria
Winnipeg
Barrie
Chatham
Hamilton
Kingston
London
Vaughan
Montreal
Québec
Saskatoon
Toronto
Windsor
Èeské Budìjovice 1
Hradec Králové
Litoměřice
Ostrava
Aalborg
Aarhus C
Hvidovre
Odense C
Amiens Cedex 1 80
Bordeaux
Clichy
Lille
Marseille
Nice
Paris
Rouen
Aachen
Berlin
Berlin Be
Bochum
Frankfurt
Hamburg
Hanover
Heidelberg
Herne
Jena
Kiel
Magdeburg
Minden
München
Münster
Neustadt
Stade
Balatonfüred
Budapest
Debrecen
Dunaújváros
Gyõr
Gyula
Gyulai Ut 18
Miskolc
Mosonmagyaróvár
Pécs
Siófok
Sopron
Szeged
Szekszárd
Székesfehérvár
Szombathely
Veszprém
Zalaegerszeg
Bangalore
Chennai
Hyderabad
Hyderabad Andh Prad
Jaipur
Kārnād
Lucknow Gpo
Ludhiana
New Delhi
Pune
Vishakapatanam
Afula
Beer Yaakov
Beersheba
Haifa
Hedera
Jerusalem
Kfar Saba
Kiryat Bialik
Nazareth
Petah-Tikv
Rehovot
Tel Aviv
Tel Litwinsky
Bunkyō City
Chikushinoshi
Fukuoka
Hiroshima
Kagoshima
Kurashiki
Kurume
Nagoya
Nishinomiya
Okayama
Osaka
Sakura
Sapporo
Tokyo
Yokkaichi
Balvi
Daugavpils
Riga
Kaunas
Klaipėda
Šiauliai
Vilnius
Vilnius Lt
Amsterdam
Ede Gld
Groningen
Leiden
Nieuwegein
Rotterdam
Auckland
Christchurch
Dunedin
Hamilton
Hastings
Bialystok
Bydgoszcz
Częstochowa
Elblag
Gdansk
Krakow
Lodz
Lublin
Opole
Skierniewice
Sopot
Szczecin
Torun
Warsaw
Bucharest
Cluj-Napoca
Iași
Târgu Mureş
Timișoara
Moscow
Novosibirsk
Omsk
Saint Petersburg
Smolensk
Yaroslavl
Belgrade
Niš
Zemun
Bratislava
Martin
Nitra
Nové Mesto nad Váhom
Prešov
Trnava
Cape Town
Cape Town West Cape
Durban
Plumstead West Cape
Pretoria Gauteng
Gothenburg
Stockholm
Donetsk
Ivano
Kharkiv
Kiev
Kyiv
Lviv
Poltava
Simferopol
Vinnitsa
Zhaporozhia 69104
Merck Sharp & Dohme LLC
INDUSTRY
Janssen Research & Development, LLC
INDUSTRY